MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Pharmacologic Options for Treating Restenosis
The role of cilostazol in the treatment of patients with infrainguinal lesions.
By Osamu Iida, MD, and Yoshimitsu Soga, MD
iVascular Luminor 18 RX DCB Launched in Japan
May 6, 2025—iVascular and Medico’s Hirata recently announced that the Vascular Luminor drug-coated balloon (DCB) has received regulatory approval from Japan’s Ministry of Health, Labour, and Welfare.
Cordis Selution SLR PTA Drug-Eluting Balloon Launched in JapanÂ
May 6, 2026—Cordis announced the launch in Japan of the Selution SLR percutaneous transluminal angioplasty (PTA) drug-eluting balloon (DEB) for the treatment of peripheral artery disease.
iVascular Initiates Trial of Luminor DCB in Japan
April 15, 2021—iVascular announced the commencement of recruitment of the first study in Japan of the company’s Luminor drug-coated balloon (DCB).
iVascular’s Luminor 18 DCB Studied in Japan to Treat Femoropopliteal Disease
July 22, 2024—iVascular announced that the first results of the SOL Japan clinical trial were presented at JET, the Japan Endovascular Treatment conference held June 14-16 in Fukuoka, Japan.
The Restenosis Conundrum
By John R. Laird, MD
